145 related articles for article (PubMed ID: 35166242)
41. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.
Siva AC; Wild MA; Kirkland RE; Nolan MJ; Lin B; Maruyama T; Yantiri-Wernimont F; Frederickson S; Bowdish KS; Xin H
Cancer Res; 2008 May; 68(10):3759-66. PubMed ID: 18483259
[TBL] [Abstract][Full Text] [Related]
42. Cub domain-containing protein 1 negatively regulates TGF-β signaling and myofibroblast differentiation.
Noskovičová N; Heinzelmann K; Burgstaller G; Behr J; Eickelberg O
Am J Physiol Lung Cell Mol Physiol; 2018 May; 314(5):L695-L707. PubMed ID: 29351434
[TBL] [Abstract][Full Text] [Related]
43. HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma.
Cao M; Gao J; Zhou H; Huang J; You A; Guo Z; Fang F; Zhang W; Song T; Zhang T
Tumour Biol; 2016 Feb; 37(2):1651-62. PubMed ID: 26307391
[TBL] [Abstract][Full Text] [Related]
44. Antibodies Against Cleaved CDCP1 Show Activity in RAS-Mutant Tumors.
Cancer Discov; 2022 Apr; 12(4):OF10. PubMed ID: 35373280
[TBL] [Abstract][Full Text] [Related]
45. Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.
Wortmann A; He Y; Christensen ME; Linn M; Lumley JW; Pollock PM; Waterhouse NJ; Hooper JD
J Biol Chem; 2011 Dec; 286(49):42303-42315. PubMed ID: 21994943
[TBL] [Abstract][Full Text] [Related]
46. The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
Forte L; Turdo F; Ghirelli C; Aiello P; Casalini P; Iorio MV; D'Ippolito E; Gasparini P; Agresti R; Belmonte B; Sozzi G; Sfondrini L; Tagliabue E; Campiglio M; Bianchi F
BMC Cancer; 2018 May; 18(1):586. PubMed ID: 29792166
[TBL] [Abstract][Full Text] [Related]
47. Loss of CDCP1 expression promotes invasiveness and poor prognosis in esophageal squamous cell carcinoma.
Sawada G; Takahashi Y; Niida A; Shimamura T; Kurashige J; Matsumura T; Ueo H; Uchi R; Takano Y; Ueda M; Hirata H; Sakimura S; Shinden Y; Eguchi H; Sudo T; Sugimachi K; Miyano S; Doki Y; Mori M; Mimori K
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S640-7. PubMed ID: 24849519
[TBL] [Abstract][Full Text] [Related]
48. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.
Uekita T; Jia L; Narisawa-Saito M; Yokota J; Kiyono T; Sakai R
Mol Cell Biol; 2007 Nov; 27(21):7649-60. PubMed ID: 17785447
[TBL] [Abstract][Full Text] [Related]
49. Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1.
Kryza T; Khan T; Lovell S; Harrington BS; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala JK; Dreyer T; Magdolen V; Reuning U; He Y; Tate EW; Hooper JD
Nat Chem Biol; 2021 Jul; 17(7):776-783. PubMed ID: 33859413
[TBL] [Abstract][Full Text] [Related]
50. Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
Harrington BS; He Y; Khan T; Puttick S; Conroy PJ; Kryza T; Cuda T; Sokolowski KA; Tse BW; Robbins KK; Arachchige BJ; Stehbens SJ; Pollock PM; Reed S; Weroha SJ; Haluska P; Salomon C; Lourie R; Perrin LC; Law RHP; Whisstock JC; Hooper JD
Theranostics; 2020; 10(5):2095-2114. PubMed ID: 32104500
[TBL] [Abstract][Full Text] [Related]
51. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.
Alajati A; Guccini I; Pinton S; Garcia-Escudero R; Bernasocchi T; Sarti M; Montani E; Rinaldi A; Montemurro F; Catapano C; Bertoni F; Alimonti A
Cell Rep; 2015 Apr; 11(4):564-76. PubMed ID: 25892239
[TBL] [Abstract][Full Text] [Related]
52. SRC kinase activator CDCP1 promotes hepatocyte growth factor-induced cell migration/invasion of a subset of breast cancer cells.
Kawase N; Sugihara A; Kajiwara K; Hiroshima M; Akamatsu K; Nada S; Matsumoto K; Ueda M; Okada M
J Biol Chem; 2022 Mar; 298(3):101630. PubMed ID: 35085554
[TBL] [Abstract][Full Text] [Related]
53. [Effect of HIF-2α on regulating CDCP1 to promote hepatocellular carcinoma metastasis].
Cao MQ; Gao JR; Huang JF; You AB; Guo ZG; Zhou HY; Fang F; Zhang W; Zhu XL; Zhang T
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):18-23. PubMed ID: 28104028
[No Abstract] [Full Text] [Related]
54. CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.
Wright HJ; Arulmoli J; Motazedi M; Nelson LJ; Heinemann FS; Flanagan LA; Razorenova OV
Oncogene; 2016 Sep; 35(36):4762-72. PubMed ID: 26876198
[TBL] [Abstract][Full Text] [Related]
55. Stratum basale keratinocyte expression of the cell-surface glycoprotein CDCP1 during epidermogenesis and its role in keratinocyte migration.
McGovern JA; Heinemann JR; Burke LJ; Dawson R; Parker TJ; Upton Z; Hooper JD; Manton KJ
Br J Dermatol; 2013 Mar; 168(3):496-503. PubMed ID: 23121233
[TBL] [Abstract][Full Text] [Related]
56. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.
Casar B; He Y; Iconomou M; Hooper JD; Quigley JP; Deryugina EI
Oncogene; 2012 Aug; 31(35):3924-38. PubMed ID: 22179830
[TBL] [Abstract][Full Text] [Related]
57. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati A; D'Ambrosio M; Troiani M; Mosole S; Pellegrini L; Chen J; Revandkar A; Bolis M; Theurillat JP; Guccini I; Losa M; Calcinotto A; De Bernardis G; Pasquini E; D'Antuono R; Sharp A; Figueiredo I; Nava Rodrigues D; Welti J; Gil V; Yuan W; Vlajnic T; Bubendorf L; Chiorino G; Gnetti L; Torrano V; Carracedo A; Camplese L; Hirabayashi S; Canato E; Pasut G; Montopoli M; Rüschoff JH; Wild P; Moch H; De Bono J; Alimonti A
J Clin Invest; 2020 May; 130(5):2435-2450. PubMed ID: 32250342
[TBL] [Abstract][Full Text] [Related]
58. The cell surface glycoprotein CDCP1 in cancer--insights, opportunities, and challenges.
Wortmann A; He Y; Deryugina EI; Quigley JP; Hooper JD
IUBMB Life; 2009 Jul; 61(7):723-30. PubMed ID: 19514048
[TBL] [Abstract][Full Text] [Related]
59. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration.
Razorenova OV; Finger EC; Colavitti R; Chernikova SB; Boiko AD; Chan CK; Krieg A; Bedogni B; LaGory E; Weissman IL; Broome-Powell M; Giaccia AJ
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):1931-6. PubMed ID: 21233420
[TBL] [Abstract][Full Text] [Related]
60. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
